Czech National Bank Has $126.55 Million Stock Position in AbbVie Inc. $ABBV

Key Points

• Czech National Bank increased its AbbVie stake by 4.5% in the second quarter, bringing its holdings to 502,897 shares valued at approximately $126.55 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie’s second-quarter earnings and revenue exceeded expectations, with revenue rising 10.2% year over year to $16.99 billion. Management also raised its revenue outlook, while analysts maintain a “Moderate Buy” consensus and a $275.70 average price target.
• Despite strong operating results and a quarterly dividend of $1.73 per share, investors remain concerned about the Apogee acquisition, including its impact on 2026 adjusted EPS and the additional debt from approximately $9.9 billion in senior notes used to fund the deal.

Czech National Bank increased its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 502,897 shares of the company's stock after purchasing an additional 21,557 shares during the period. AbbVie makes up 0.7% of Czech National Bank's holdings, making the stock its 24th biggest holding. Czech National Bank's holdings in AbbVie were worth $126,549,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after buying an additional 3,032,438 shares during the period. State Street Corp raised its position in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company's stock valued at $18,494,193,000 after buying an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. Bank of America Corp DE lifted its holdings in shares of AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock worth $5,900,617,000 after acquiring an additional 356,394 shares during the period. Finally, Norges Bank acquired a new stake in shares of AbbVie during the 4th quarter worth approximately $5,865,055,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

AbbVie Price Performance

ABBV stock opened at $243.64 on Friday. The company has a 50 day simple moving average of $241.40 and a 200 day simple moving average of $224.82. The stock has a market cap of $430.46 billion, a price-to-earnings ratio of 68.82, a P/E/G ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie's dividend payout ratio is presently 195.48%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wells Fargo & Company lifted their price objective on shares of AbbVie from $260.00 to $295.00 and gave the company an "overweight" rating in a research note on Friday, July 10th. HSBC restated a "buy" rating and set a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Morgan Stanley reiterated an "overweight" rating and issued a $296.00 price target on shares of AbbVie in a research note on Monday. Bank of America boosted their price target on AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Finally, Royal Bank Of Canada upped their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $275.70.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source